Literature DB >> 12709413

Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma.

Nadia Coltella1, Maria Cristina Manara, Vanessa Cerisano, Livio Trusolino, Maria Flavia Di Renzo, Katia Scotlandi, Riccardo Ferracini.   

Abstract

Signal transduction downstream HGF receptor (MET) activation involves multiple pathways that account for mitogenesis, motility and morphogenesis in a cell type-dependent fashion. MET receptor is aberrantly expressed in almost 100% of human osteosarcomas. We analyzed the effect of the MET receptor activation in five human osteosarcoma cell lines evaluating the levels of HGF-dependent activation of MAPK and PKB/AKT as biochemical readouts of mitogenic and invasive responses, respectively. All the cell lines tested expressed high levels of the MET proto-oncogene. Four cell lines showed activation of the MAPK cascade upon HGF stimulation, suggesting that this growth factor serves a common proliferative function in osteosarcomas. Two lines showed activation of PKB/AKT that is known to be involved in migration mediated by HGF receptor. Accordingly, cell lines where MAPK cascade was activated responded to HGF with increased proliferation, while induction and inhibition of PKB/AKT activity corresponded to acquisition or block of the invasive-motile response to HGF, respectively. Both the HGF dependent responses were reverted by the specific MET inhibitor K252a. These data show that HGF activates both the mitogen and motogen machinery in osteosarcoma cells and suggest that HGF might promote their malignant behavior by concomitant activation of different pathways and biological functions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12709413     DOI: 10.1096/fj.02-0576fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  18 in total

1.  Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma.

Authors:  Gregory A Watson; Xinglu Zhang; Michael T Stang; Ryan M Levy; Pierre E Queiroz de Oliveira; William E Gooding; James G Christensen; Steven J Hughes
Journal:  Neoplasia       Date:  2006-11       Impact factor: 5.715

2.  Genomic implications of H(2)O (2) for cell proliferation and growth of Caco-2 cells.

Authors:  Theresa A Herring; Susan L Cuppett; Janos Zempleni
Journal:  Dig Dis Sci       Date:  2007-06-28       Impact factor: 3.199

Review 3.  Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro.

Authors:  Patrick J Messerschmitt; Ashley N Rettew; Robert E Brookover; Ryan M Garcia; Patrick J Getty; Edward M Greenfield
Journal:  Clin Orthop Relat Res       Date:  2008-07-08       Impact factor: 4.176

4.  A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).

Authors:  James I Geller; John P Perentesis; Xiaowei Liu; Charles G Minard; Rachel A Kudgus; Joel M Reid; Elizabeth Fox; Susan M Blaney; Brenda J Weigel
Journal:  Pediatr Blood Cancer       Date:  2017-04-27       Impact factor: 3.167

5.  Synergistic effect of low-dose cucurbitacin B and low-dose methotrexate for treatment of human osteosarcoma.

Authors:  Dhong Hyun Lee; Nils H Thoennissen; Catherine Goff; Gabriela B Iwanski; Charles Forscher; Ngan B Doan; Jonathan W Said; H Phillip Koeffler
Journal:  Cancer Lett       Date:  2011-03-26       Impact factor: 8.679

6.  MET overexpressing chordomas frequently exhibit polysomy of chromosome 7 but no MET activation through sarcoma-specific gene fusions.

Authors:  Florian Grabellus; Margarethe J Konik; Karl Worm; Sien-Yi Sheu; Johannes A P van de Nes; Sebastian Bauer; Werner Paulus; Rupert Egensperger; Kurt W Schmid
Journal:  Tumour Biol       Date:  2010-03-06

Review 7.  Gangliosides as Signaling Regulators in Cancer.

Authors:  Norihiko Sasaki; Masashi Toyoda; Toshiyuki Ishiwata
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923

Review 8.  Heterogeneous Circulating Tumor Cells in Sarcoma: Implication for Clinical Practice.

Authors:  Chiara Agnoletto; Chiara Caruso; Cecilia Garofalo
Journal:  Cancers (Basel)       Date:  2021-05-02       Impact factor: 6.639

9.  Dkk-3, a secreted wnt antagonist, suppresses tumorigenic potential and pulmonary metastasis in osteosarcoma.

Authors:  Carol H Lin; Yi Guo; Samia Ghaffar; Peter McQueen; Jonathan Pourmorady; Alexander Christ; Kevin Rooney; Tao Ji; Ramez Eskander; Xiaolin Zi; Bang H Hoang
Journal:  Sarcoma       Date:  2013-02-10

10.  Bone sarcomas: from biology to targeted therapies.

Authors:  Nathalie Gaspar; Angela Di Giannatale; Birgit Geoerger; Françoise Redini; Nadège Corradini; Natacha Enz-Werle; Franck Tirode; Perrine Marec-Berard; Jean-Claude Gentet; Valérie Laurence; Sophie Piperno-Neumann; Odile Oberlin; Laurence Brugieres
Journal:  Sarcoma       Date:  2012-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.